collection
MENU ▼
Read by QxMD icon Read
search

diabetes treatment

shared collection
19 papers 25 to 100 followers
https://www.readbyqxmd.com/read/28325798/management-of-inpatient-hyperglycemia-and-diabetes-in-older-adults
#1
Guillermo E Umpierrez, Francisco J Pasquel
Adults aged 65 years and older are the fastest growing segment of the U.S. population, and their number is expected to double to 89 million between 2010 and 2050. The prevalence of diabetes in hospitalized adults aged 65-75 years and over 80 years of age has been estimated to be 20% and 40%, respectively. Similar to general populations, the presence of hyperglycemia and diabetes in elderly patients is associated with increased risk of hospital complications, longer length of stay, and increased mortality compared with subjects with normoglycemia...
April 2017: Diabetes Care
https://www.readbyqxmd.com/read/28288484/pharmacologic-therapy-for-type-2-diabetes-synopsis-of-the-2017-american-diabetes-association-standards-of-medical-care-in-diabetes
#2
James J Chamberlain, William H Herman, Sandra Leal, Andrew S Rhinehart, Jay H Shubrook, Neil Skolnik, Rita Rastogi Kalyani
Description: The American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: For the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence...
March 14, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/27640062/insulin-monotherapy-compared-with-the-addition-of-oral-glucose-lowering-agents-to-insulin-for-people-with-type-2-diabetes-already-on-insulin-therapy-and-inadequate-glycaemic-control
#3
REVIEW
Rimke C Vos, Mariëlle Jp van Avendonk, Hanneke Jansen, Alexander N Goudswaard, Maureen van den Donk, Kees Gorter, Anneloes Kerssen, Guy Ehm Rutten
BACKGROUND: It is unclear whether people with type 2 diabetes mellitus on insulin monotherapy who do not achieve adequate glycaemic control should continue insulin as monotherapy or can benefit from adding oral glucose-lowering agents to the insulin therapy. OBJECTIVES: To assess the effects of insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin monotherapy for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control...
September 18, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28223445/diabetic-retinopathy-a-position-statement-by-the-american-diabetes-association
#4
REVIEW
Sharon D Solomon, Emily Chew, Elia J Duh, Lucia Sobrin, Jennifer K Sun, Brian L VanderBeek, Charles C Wykoff, Thomas W Gardner
No abstract text is available yet for this article.
March 2017: Diabetes Care
https://www.readbyqxmd.com/read/28167928/clinical-review-of-antidiabetic-drugs-implications-for-type-2-diabetes-mellitus-management
#5
REVIEW
Arun Chaudhury, Chitharanjan Duvoor, Vijaya Sena Reddy Dendi, Shashank Kraleti, Aditya Chada, Rahul Ravilla, Asween Marco, Nawal Singh Shekhawat, Maria Theresa Montales, Kevin Kuriakose, Appalanaidu Sasapu, Alexandria Beebe, Naveen Patil, Chaitanya K Musham, Govinda Prasad Lohani, Wasique Mirza
Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/). Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition chiefly characterized by hyperglycemia. Impaired insulin secretion, resistance to tissue actions of insulin, or a combination of both are thought to be the commonest reasons contributing to the pathophysiology of T2DM, a spectrum of disease originally arising from tissue insulin resistance and gradually progressing to a state characterized by complete loss of secretory activity of the beta cells of the pancreas...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/28190580/type-2-diabetes
#6
REVIEW
Sudesna Chatterjee, Kamlesh Khunti, Melanie J Davies
415 million people live with diabetes worldwide, and an estimated 193 million people have undiagnosed diabetes. Type 2 diabetes accounts for more than 90% of patients with diabetes and leads to microvascular and macrovascular complications that cause profound psychological and physical distress to both patients and carers and put a huge burden on health-care systems. Despite increasing knowledge regarding risk factors for type 2 diabetes and evidence for successful prevention programmes, the incidence and prevalence of the disease continues to rise globally...
February 10, 2017: Lancet
https://www.readbyqxmd.com/read/28145083/the-effect-of-adding-metformin-to-insulin-therapy-for-type-1-diabetes-mellitus-children-a-systematic-review-and-meta-analysis
#7
REVIEW
Reem A Al Khalifah, Abdulrahman Alnhdi, Hassan Alghar, Mohammad Alanazi, Ivan D Florez
We aimed to assess the effectiveness of adding metformin to insulin in type 1 diabetes mellitus (T1DM) children for improving metabolic outcomes. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) conducted on children age 6 to 19 years who are diagnosed with T1DM, and examined the effect of adding Metformin to standard insulin therapy. We performed literature searches on Ovid Midline, Ovid Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) from the date of inception of the database to February 15, 2016...
February 1, 2017: Pediatric Diabetes
https://www.readbyqxmd.com/read/28019064/novel-antidiabetic-medications-for-non-alcoholic-fatty-liver-disease-with-type-2-diabetes-mellitus
#8
REVIEW
Yoshio Sumida, Yuya Seko, Masashi Yoneda
Liver-related diseases are the leading causes of death in patients with type 2 diabetes mellitus (T2DM) in Japan. Type 2 diabetes mellitus is closely associated with non-alcoholic fatty liver disease (NAFLD), which is the most prevalent chronic liver disease worldwide. Non-alcoholic steatohepatitis (NASH), a severe form of NAFLD, can lead to hepatocellular carcinoma and hepatic failure. Non-alcoholic steatohepatitis can be called "diabetic hepatopathy". There are no established pharmacotherapies for NAFLD/NASH patients with T2DM...
December 26, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28140674/concentrated-insulins-clinical-applications-use-in-practical-settings
#9
(no author information available yet)
No abstract text is available yet for this article.
January 2, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/27999003/diabetic-neuropathy-a-position-statement-by-the-american-diabetes-association
#10
REVIEW
Rodica Pop-Busui, Andrew J M Boulton, Eva L Feldman, Vera Bril, Roy Freeman, Rayaz A Malik, Jay M Sosenko, Dan Ziegler
No abstract text is available yet for this article.
January 2017: Diabetes Care
https://www.readbyqxmd.com/read/27979889/2-classification-and-diagnosis-of-diabetes
#11
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
January 2017: Diabetes Care
https://www.readbyqxmd.com/read/27465265/pioglitazone-prevents-diabetes-in-patients-with-insulin-resistance-and-cerebrovascular-disease
#12
Silvio E Inzucchi, Catherine M Viscoli, Lawrence H Young, Karen L Furie, Mark Gorman, Anne M Lovejoy, Samuel Dagogo-Jack, Faramarz Ismail-Beigi, Mary T Korytkowski, Richard E Pratley, Gregory G Schwartz, Walter N Kernan
OBJECTIVE: The Insulin Resistance Intervention after Stroke (IRIS) trial recently found that pioglitazone reduced risk for stroke and myocardial infarction in patients with insulin resistance but without diabetes who had had a recent ischemic stroke or transient ischemic attack (TIA). This report provides detailed results on the metabolic effects of pioglitazone and the trial's prespecified secondary aim of diabetes prevention. RESEARCH DESIGN AND METHODS: A total of 3,876 patients with recent ischemic stroke or TIA, no history of diabetes, fasting plasma glucose (FPG) <126 mg/dL, and insulin resistance by homeostasis model assessment of insulin resistance (HOMA-IR) score >3...
October 2016: Diabetes Care
https://www.readbyqxmd.com/read/27339889/pharmacology-and-therapeutic-implications-of-current-drugs-for-type-2-diabetes-mellitus
#13
REVIEW
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey
Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-care systems. Improving metabolic control to approach normal glycaemia (where practical) greatly benefits long-term prognoses and justifies early, effective, sustained and safety-conscious intervention. Improvements in the understanding of the complex pathogenesis of T2DM have underpinned the development of glucose-lowering therapies with complementary mechanisms of action, which have expanded treatment options and facilitated individualized management strategies...
October 2016: Nature Reviews. Endocrinology
https://www.readbyqxmd.com/read/27359293/use-of-metformin-in-clinical-endocrinology
#14
J Michael Gonzalez-Campoy
CKD = chronic kidney disease DM = diabetes mellitus eGFR = estimated glomerular filtration rate FDA = Food & Drug Administration.
August 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27210018/obviating-much-of-the-need-for-insulin-therapy-in-type-2-diabetes-mellitus-a-re-assessment-of-insulin-therapy-s-safety-profile
#15
REVIEW
Stanley S Schwartz, Paul S Jellinger, Mary E Herman
Current processes of care for diabetes mellitus (DM) were shaped during the era when insulin therapy was considered inexorable to the management of advanced stage type 2 (T2DM), though this no longer appears to be categorically true. There are also dashed hopes that insulin therapy can prevent or stall diabetes. While exogenous insulin remains a life-sparing tool for fully insulin-dependent DM, insulin therapy-induced hyperinsulinemia now appears to contribute to serious safety issues beyond hypoglycemia and weight gain...
August 2016: Postgraduate Medicine
https://www.readbyqxmd.com/read/26798149/mechanism-of-metformin-a-tale-of-two-sites
#16
Ruisheng Song
No abstract text is available yet for this article.
February 2016: Diabetes Care
https://www.readbyqxmd.com/read/27063928/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of%C3%A2-azp-531-a-first-in-class-analogue-of-unacylated-ghrelin-in%C3%A2-healthy-and-overweight-obese-subjects-and-subjects-with-type-2-diabetes
#17
S Allas, T Delale, N Ngo, M Julien, P Sahakian, J Ritter, T Abribat, A J van der Lely
AIM: To explore the safety, pharmacokinetics and pharmacodynamics in humans of the unacylated ghrelin analogue AZP-531, designed to improve glycaemic control and reduce weight. METHODS: Assessments, including glucose measurements, were performed in a three-part randomized study. In Part A, healthy subjects [n = 44, age 18-50 years, body mass index (BMI) 20-28 kg/m(2) ] received a single subcutaneous dose of 0.3, 3, 15, 30, 60 or 120 µg/kg AZP-531 or placebo...
September 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27088241/diabetes-medications-as-monotherapy-or-metformin-based-combination-therapy-for-type-2-diabetes-a-systematic-review-and-meta-analysis
#18
Nisa M Maruthur, Eva Tseng, Susan Hutfless, Lisa M Wilson, Catalina Suarez-Cuervo, Zackary Berger, Yue Chu, Emmanuel Iyoha, Jodi B Segal, Shari Bolen
BACKGROUND: Clinicians and patients need updated evidence on the comparative effectiveness and safety of diabetes medications to make informed treatment choices. PURPOSE: To evaluate the comparative effectiveness and safety of monotherapy (thiazolidinediones, metformin, sulfonylureas, dipeptidyl peptidase-4 [DPP-4] inhibitors, sodium-glucose cotransporter 2 [SGLT-2] inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists) and selected metformin-based combinations in adults with type 2 diabetes...
June 7, 2016: Annals of Internal Medicine
https://www.readbyqxmd.com/read/25645672/a-real-world-comparison-of-sulfonylurea-and-insulin-vs-incretin-based-treatments-in-patients-not-controlled-on-prior-metformin-monotherapy
#19
MULTICENTER STUDY
Anselm K Gitt, Peter Bramlage, Steffen Schneider, Diethelm Tschöpe
AIMS: Metformin is the first line drug for patients diagnosed with type-2 diabetes; however, the impact of different treatment escalation strategies after metformin failure has thus far not been investigated in a real world situation. The registry described herein goes some way to clarifying treatment outcomes in such patients. METHODS: DiaRegis is a multicentre registry including 3,810 patients with type-2 diabetes. For the present analysis we selected patients being treated with metformin monotherapy at baseline (n = 1,373), with the subsequent addition of incretin-based drugs (Met/Incr; n = 783), sulfonylureas (Met/SU; n = 255), or insulin (n = 220)...
2015: Cardiovascular Diabetology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"